JP2017506666A - 高インスリン血症に関連した症状の処置 - Google Patents

高インスリン血症に関連した症状の処置 Download PDF

Info

Publication number: JP2017506666A
Authority: JP; Japan
Prior art keywords: alkyl; alkylene; aryl; heteroaryl; heterocycloalkyl
Prior art date: 2014-02-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

JP2016554661A

Other languages

English (en)

Japanese (ja)

Other versions

JP2017506666A5 (2

Inventor

ランドー，スティーブン，ビー．

ケーギー，マイケル

Original Assignee

テンシャセラピューティクス，インコーポレイテッド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-02-28

Filing date

2015-02-27

Publication date

2017-03-09

2015-02-27 Application filed by テンシャセラピューティクス，インコーポレイテッド, テンシャセラピューティクス，インコーポレイテッド filed Critical テンシャセラピューティクス，インコーポレイテッド

2017-03-09 Publication of JP2017506666A publication Critical patent/JP2017506666A/ja

2018-02-22 Publication of JP2017506666A5 publication Critical patent/JP2017506666A5/ja

Status Withdrawn legal-status Critical Current

Links

MQIXMONQZBAABB-HNNXBMFYSA-N CC(C)(C)OC(C[C@@H](c1nnc(C(F)(F)F)[n]1-c1c2c(C)c(C)[s]1)N=C2c(cc1)ccc1Cl)=O Chemical compound CC(C)(C)OC(C[C@@H](c1nnc(C(F)(F)F)[n]1-c1c2c(C)c(C)[s]1)N=C2c(cc1)ccc1Cl)=O MQIXMONQZBAABB-HNNXBMFYSA-N 0.000 description 1
NEOVTYQDNTUFDO-SFHVURJKSA-N CC(C)(C)OC(C[C@@H](c1nnc(C)[n]1-c1c2c(C)c(C)[s]1)N=C2c1ccc(C)cc1)=O Chemical compound CC(C)(C)OC(C[C@@H](c1nnc(C)[n]1-c1c2c(C)c(C)[s]1)N=C2c1ccc(C)cc1)=O NEOVTYQDNTUFDO-SFHVURJKSA-N 0.000 description 1
ACFYVOWECVLYMP-KRWDZBQOSA-N CC(C)(C)OC(C[C@@H](c1nnc(C)[n]1-c1c2cc[s]1)N=C2c1ccc(C)cc1)=O Chemical compound CC(C)(C)OC(C[C@@H](c1nnc(C)[n]1-c1c2cc[s]1)N=C2c1ccc(C)cc1)=O ACFYVOWECVLYMP-KRWDZBQOSA-N 0.000 description 1
DNMKBLRJHYUGOG-SFHVURJKSA-N CC(C)(C)OC(C[C@@H](c1nnc(COC)[n]1-c1c2c(C)c(C)[s]1)N=C2c1ccc(C)cc1)=O Chemical compound CC(C)(C)OC(C[C@@H](c1nnc(COC)[n]1-c1c2c(C)c(C)[s]1)N=C2c1ccc(C)cc1)=O DNMKBLRJHYUGOG-SFHVURJKSA-N 0.000 description 1
RKJJOHJEISURKY-ZENAZSQFSA-N CCC1N2c([s]c(C)c3C)c3C(c(cc3)ccc3Cl)=N[C@@H](CC(OC(C)(C)C)=O)C2=NN1 Chemical compound CCC1N2c([s]c(C)c3C)c3C(c(cc3)ccc3Cl)=N[C@@H](CC(OC(C)(C)C)=O)C2=NN1 RKJJOHJEISURKY-ZENAZSQFSA-N 0.000 description 1
XOFSUERZLYLNTE-FQEVSTJZSA-N Cc1c(C)[s]c-2c1C(c(cc1)ccc1Cl)=N[C@@H](CC(NCCCNCCNC)=O)c1nnc(C)[n]-21 Chemical compound Cc1c(C)[s]c-2c1C(c(cc1)ccc1Cl)=N[C@@H](CC(NCCCNCCNC)=O)c1nnc(C)[n]-21 XOFSUERZLYLNTE-FQEVSTJZSA-N 0.000 description 1
CVPIVJUAWTWRAZ-NRFANRHFSA-N Cc1c(C)[s]c-2c1C(c(cc1)ccc1Cl)=N[C@@H](CC(NCCN1CCN(C)CC1)=O)c1nnc(C)[n]-21 Chemical compound Cc1c(C)[s]c-2c1C(c(cc1)ccc1Cl)=N[C@@H](CC(NCCN1CCN(C)CC1)=O)c1nnc(C)[n]-21 CVPIVJUAWTWRAZ-NRFANRHFSA-N 0.000 description 1
KULOTNHGHJGDQB-FQEVSTJZSA-N Cc1c(C)[s]c-2c1C(c(cc1)ccc1Cl)=N[C@@H](CC(NCCN1CCOCC1)=O)c1nnc(C)[n]-21 Chemical compound Cc1c(C)[s]c-2c1C(c(cc1)ccc1Cl)=N[C@@H](CC(NCCN1CCOCC1)=O)c1nnc(C)[n]-21 KULOTNHGHJGDQB-FQEVSTJZSA-N 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Hematology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Dermatology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

JP2016554661A 2014-02-28 2015-02-27 高インスリン血症に関連した症状の処置 Withdrawn JP2017506666A (ja)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US201461946682P	2014-02-28	2014-02-28
US61/946,682		2014-02-28
US201462019777P	2014-07-01	2014-07-01
US62/019,777		2014-07-01
US201462054620P	2014-09-24	2014-09-24
US62/054,620		2014-09-24
PCT/US2015/018118 WO2015131113A1 (en)	2014-02-28	2015-02-27	Treatment of conditions associated with hyperinsulinaemia

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2018222642A Division JP6629947B2 (ja)	2014-02-28	2018-11-28	高インスリン血症に関連した症状の処置

Publications (2)

Publication Number	Publication Date
JP2017506666A true JP2017506666A (ja)	2017-03-09
JP2017506666A5 JP2017506666A5 (2)	2018-02-22

Family

ID=52693055

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
JP2016554661A Withdrawn JP2017506666A (ja)	2014-02-28	2015-02-27	高インスリン血症に関連した症状の処置
JP2018222642A Expired - Fee Related JP6629947B2 (ja)	2014-02-28	2018-11-28	高インスリン血症に関連した症状の処置

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2018222642A Expired - Fee Related JP6629947B2 (ja)	2014-02-28	2018-11-28	高インスリン血症に関連した症状の処置

Country Status (12)

Country	Link
US (1)	US10925881B2 (2)
EP (1)	EP3110424A1 (2)
JP (2)	JP2017506666A (2)
KR (1)	KR20160130778A (2)
CN (1)	CN106456653A (2)
AU (1)	AU2015222805B2 (2)
CA (1)	CA2940472A1 (2)
IL (1)	IL247354B (2)
MX (1)	MX377534B (2)
RU (1)	RU2722179C2 (2)
SG (1)	SG11201607108XA (2)
WO (1)	WO2015131113A1 (2)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2902030T3 (pl)	2010-05-14	2017-07-31	Dana-Farber Cancer Institute, Inc.	Związki tienotriazolodiazepinowe do leczenia nowotworu
MX354217B (es)	2010-05-14	2018-02-19	Dana Farber Cancer Inst Inc	Composiciones y metodos para el tratamiento de leucemia.
CA2929652A1 (en)	2013-11-08	2015-05-14	Dana-Farber Cancer Institute, Inc.	Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
CA2936865A1 (en)	2014-01-31	2015-08-06	Dana-Farber Cancer Institute, Inc.	Diaminopyrimidine benzenesulfone derivatives and uses thereof
WO2015117087A1 (en)	2014-01-31	2015-08-06	Dana-Farber Cancer Institute, Inc.	Uses of diazepane derivatives
SG11201607108XA (en)	2014-02-28	2016-09-29	Tensha Therapeutics Inc	Treatment of conditions associated with hyperinsulinaemia
BR112017008714A2 (pt)	2014-10-27	2017-12-19	Tensha Therapeutics Inc	inibidores de bromodomínio
CA2989313A1 (en)	2015-06-26	2016-12-29	Tensha Therapeutics, Inc.	Treatment of nut midline carcinoma
RU2018112953A (ru) *	2015-09-11	2019-10-14	Дана-Фарбер Кэнсер Инститьют, Инк.	Ацетамидтиенотриазолодиазепины и пути их применения
HK1256417A1 (zh)	2015-09-11	2019-09-20	达纳-法伯癌症研究所股份有限公司	氰基噻吩并三唑并二氮杂环庚三烯及其用途
MX2018006499A (es)	2015-11-25	2018-08-01	Dana Farber Cancer Inst Inc	Inhibidores de bromodominio bivalentes y usos de los mismos.
KR20190092429A (ko) *	2016-12-16	2019-08-07	에프. 호프만-라 로슈 아게	다이아제핀 유도체의 제조 방법
CN111094263A (zh) *	2017-09-14	2020-05-01	豪夫迈·罗氏有限公司	可用于制造药物的新化合物
MX2020013608A (es)	2018-06-13	2021-03-09	Worg Pharmaceuticals Hangzhou Co Ltd	Preparacion de derivados de triazepina condensados y su uso como inhibidores de bet.
CN111253871A (zh) *	2020-03-13	2020-06-09	东莞市永益诚电子有限公司	一种钢化膜及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006129623A1 (ja) *	2005-05-30	2006-12-07	Mitsubishi Tanabe Pharma Corporation	チエノトリアゾロジアゼピン化合物及びその医薬としての用途
WO2009084692A1 (ja) *	2007-12-28	2009-07-09	Nippon Telegraph And Telephone Corporation	可変焦点レンズ
WO2012050907A2 (en) *	2010-09-28	2012-04-19	The Regents Of The University Of California	Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
JP2013527177A (ja) *	2010-05-14	2013-06-27	ダナ−ファーバーキャンサーインスティテュート，インコーポレイテッド	代謝を調節する組成物および方法

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2951540A (en)	1956-11-05	1960-09-06	Gen Motors Corp	Propeller brake
US3709898A (en)	1971-02-09	1973-01-09	Upjohn Co	Process for the production of triazolobenzodiazepines and intermediates
US3681343A (en)	1971-05-11	1972-08-01	Upjohn Co	6-phenyl-s-triazolo{8 4,3-a{9 {8 1,4{9 {0 benzodiazepines
US3812259A (en)	1971-08-09	1974-05-21	Upjohn Co	Animal feed and process
CH622019A5 (en)	1975-10-23	1981-03-13	Upjohn Co	Process for the preparation of aminotriazolobenzodiazepines
FR2329668A1 (fr)	1975-10-27	1977-05-27	Upjohn Co	Procede de preparation d'aminotriazolobenzodiazepines
EP0087850A1 (en)	1982-01-04	1983-09-07	The Upjohn Company	Benzodiazepines for anti-hypertensive use
DE3435973A1 (de)	1984-10-01	1986-04-10	Boehringer Ingelheim KG, 6507 Ingelheim	Diazepine enthaltende pharmazeutische zusammensetzungen mit paf-antagonistischer wirkung
DE3724164A1 (de)	1986-07-25	1988-01-28	Boehringer Ingelheim Kg	Neue 1,4-benzodiazepine, ihre herstellung und verwendung
WO1988009333A1 (fr)	1987-05-28	1988-12-01	Yoshitomi Pharmaceutical Industries, Ltd.	Compose a base de thieno(triazolo)diazepine et applications medicales de ce compose
JPH0676326B2 (ja)	1988-05-24	1994-09-28	吉富製薬株式会社	循環器系疾患治療薬
EP0368175A1 (de)	1988-11-06	1990-05-16	Boehringer Ingelheim Kg	3S,7S-3-(Morpholinocarbonyl)-5-(2-chlorphenyl)-7,10-dimethyl-3,4-dihydro-2H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin.
EP0387613A1 (de)	1989-03-03	1990-09-19	Boehringer Ingelheim Kg	Neue Thienodiazepine
YU133090A (sh)	1989-07-12	1993-10-20	Boehringer Ingelheim Kg.	Novi heteroazepini s paf-antaganostičnim učinkom in postopek za njihovo pripravo
DE4010528A1 (de)	1990-04-02	1991-10-17	Boehringer Ingelheim Kg	Praeparativ chromatographisches trennverfahren zur herstellung enantiomerenreiner hetrazepine
EP0638560A4 (en)	1991-10-11	1995-03-29	Yoshitomi Pharmaceutical	MEDICINE FOR OSTEOPOROSIS AND DIAZEPINE COMPOUND *.
WO1994006802A1 (fr)	1992-09-18	1994-03-31	Yoshitomi Pharmaceutical Industries, Ltd.	Compose de thienodiazepine et son utilisation medicinale
CA2159344A1 (en)	1993-03-30	1994-10-13	Minoru Moriwaki	Cell adhesion inhibitor and thienotriazolodiazepine compound
WO1995032963A1 (en)	1994-06-01	1995-12-07	Yoshitomi Pharmaceutical Industries, Ltd.	Thienylazole compound and thienotriazolodiazepine compound
PT801651E (pt)	1995-01-06	2001-12-28	Hoffmann La Roche	Hidroximetil-imidazodiazepinas e seus esteres
US5730723A (en)	1995-10-10	1998-03-24	Visionary Medical Products Corporation, Inc.	Gas pressured needle-less injection device and method
FI974437A7 (fi) *	1995-06-06	1997-12-05	Pfizer	Substituoituja N-(indoli-2-karbonyyli)amideja ja johdannaisia glykogee nifosforylaasi-inhibiittoreina
CA2224062C (en) *	1995-06-06	2001-09-04	Pfizer Limited	Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
DK0853480T3 (da)	1995-09-09	2003-05-05	Hoffmann La Roche	Anvendelse af en thienotriazolodiazepin til forøgelse af apolipoprotein A-I-niveauer
GB9607549D0 (en)	1996-04-11	1996-06-12	Weston Medical Ltd	Spring-powered dispensing device
PL330635A1 (en)	1996-06-12	1999-05-24	Japan Tobacco Inc	Inhibitor of cytokin production, triazepin compound and intermediate compounds used for obtaining the last mentioned one
US5693641A (en)	1996-08-16	1997-12-02	Berlex Laboratories Inc.	Bicyclic pyrimidine derivatives and their use as anti-coagulants
DE69717160T2 (de)	1996-09-13	2003-05-08	Mitsubishi Pharma Corp., Osaka	Thienotriazolodiazepinverbindungen und ihre medizinischen anwendungen
US6444664B1 (en)	1997-04-18	2002-09-03	Nederlandse Organisatie Voor Toegepast - Natuurweten Schappelijk Onderzoek (Tno)	Method for controlling the plasma level of lipoproteins to treat alzheimeris disease
JPH11228576A (ja)	1997-12-10	1999-08-24	Japan Tobacco Inc	アポトーシス抑制剤
IT1298087B1 (it)	1998-01-08	1999-12-20	Fiderm S R L	Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
FR2779652B1 (fr)	1998-06-15	2001-06-08	Sod Conseils Rech Applic	Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique
KR20000016732A (en)	1998-12-12	2000-03-25	Japan Tobacco Inc	Cytokine production inhibitors, triazepine compounds, and intermediates thereof
HK1047236A1 (zh)	1999-05-14	2003-02-14	Imclone Llc	用表皮生长因子受体拮抗剂治疗难治的人肿瘤
US6312215B1 (en)	2000-02-15	2001-11-06	United Technologies Corporation	Turbine engine windmilling brake
US7589167B2 (en)	2000-02-22	2009-09-15	J. David Gladstone Institutes	ZA loops of bromodomains
WO2001095912A1 (fr)	2000-06-16	2001-12-20	Mitsubishi Pharma Corporation	Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph
AU2001270297A1 (en)	2000-06-30	2002-01-14	Neurogen Corporation	2-phenylimidazo(1,2-a)pyridine derivatives: a new class of gaba brain receptor ligands
US20060142257A1 (en)	2001-01-19	2006-06-29	Eberhard Nieschlag	Male contraceptive formulation comprising norethisterone
US6979682B2 (en)	2001-02-23	2005-12-27	Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Platelet-activating factor antagonist inhibition of angiogenesis and tumor growth induced by basic fibroblast
US20030216758A1 (en)	2001-12-28	2003-11-20	Angiotech Pharmaceuticals, Inc.	Coated surgical patches
GB0206215D0 (en)	2002-03-15	2002-05-01	Novartis Ag	Organic compounds
US6861422B2 (en)	2003-02-26	2005-03-01	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
ES2545666T3 (es)	2003-02-27	2015-09-14	Abbvie Inc.	5,10-Dihidro-11H-dibenzo[b,e][1,4]diazepin-11-ona como inhibidores de quinasa
GB0305929D0 (en)	2003-03-14	2003-04-23	Novartis Ag	Organic compounds
CA2527957A1 (en)	2003-06-02	2005-01-06	Ohio University	Use of genes differentially expressed during aging of liver for treatment and diagnosis
WO2005002526A2 (en)	2003-07-01	2005-01-13	President And Fellows Of Harvard College	Method and compositions for treatment of viral infections
MXPA06003054A (es)	2003-09-18	2006-05-31	Novartis Ag	2,4-di-(fenil-amino)-pirimidinas utiles en el tratamiento de trastornos proliferativos.
EP1528056A1 (en)	2003-10-29	2005-05-04	Academisch Ziekenhuis bij de Universiteit van Amsterdam	Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
US7759485B2 (en)	2004-08-14	2010-07-20	Boehringer Ingelheim International Gmbh	Process for the manufacture of dihydropteridinones
US20060035903A1 (en)	2004-08-14	2006-02-16	Boehringer Ingelheim International Gmbh	Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en)	2004-08-14	2006-03-16	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation
US20060074088A1 (en)	2004-08-14	2006-04-06	Boehringer Ingelheim International Gmbh	Dihydropteridinones for the treatment of cancer diseases
CN1759834B (zh)	2004-09-17	2010-06-23	中国医学科学院医药生物技术研究所	黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
US8624027B2 (en)	2005-05-12	2014-01-07	Abbvie Inc.	Combination therapy for treating cancer and diagnostic assays for use therein
WO2007014838A1 (en)	2005-08-03	2007-02-08	Boehringer Ingelheim International Gmbh	Dihydropteridinones in the treatment of respiratory diseases
CN103626742B (zh)	2005-11-01	2017-04-26	塔格根公司	激酶的联-芳基间-嘧啶抑制剂
US8133900B2 (en)	2005-11-01	2012-03-13	Targegen, Inc.	Use of bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en)	2005-11-01	2013-12-10	Targegen, Inc.	Bi-aryl meta-pyrimidine inhibitors of kinases
WO2007056117A1 (en)	2005-11-04	2007-05-18	Wyeth	Antineoplastic combinations of temsirolimus and sunitinib malate
SI1962830T1 (sl)	2005-12-23	2013-07-31	Glaxosmithkline Llc	Azaindolni inhibitorji kinaz Aurora
WO2007082806A1 (en)	2006-01-17	2007-07-26	F. Hoffmann-La Roche Ag	Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine useful for the treatment of alzheimer’s disease via gaba receptors
TW200804389A (en)	2006-02-14	2008-01-16	Vertex Pharma	Dihydrodiazepines useful as inhibitors of protein kinases
US20070218135A1 (en)	2006-03-14	2007-09-20	Glenmark Pharmaceuticals Limited	Sustained release matrix pharmaceutical composition
RU2008147269A (ru)	2006-05-03	2010-06-10	Новартис АГ (CH)	Применение органических соединений
US7621117B2 (en)	2006-06-19	2009-11-24	Pratt & Whitney Canada Corp.	Apparatus and method for controlling engine windmilling
ATE543819T1 (de)	2006-10-19	2012-02-15	Signal Pharm Llc	Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit
US8338464B2 (en)	2006-11-30	2012-12-25	Albert Einstein College Of Medicine Of Yeshiva University	Small molecule inhibitors of BCL6
JP2008156311A (ja)	2006-12-26	2008-07-10	Institute Of Physical & Chemical Research	Ｂｒｄ２ブロモドメイン結合剤
TWI618544B (zh)	2006-12-26	2018-03-21	藍瑟斯醫學影像公司	使心臟神經分布顯像之配位體
WO2008137081A1 (en)	2007-05-02	2008-11-13	The Trustees Of Columbia University In The City Of New York	Substituted ( 5, 6 ) -dihydronaphraalenyl compounds as reversible male contraceptives
KR20080107050A (ko)	2007-06-05	2008-12-10	울산대학교 산학협력단	항-ｃｄ１３７ 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물
EP2234986A2 (en)	2007-12-20	2010-10-06	Cellzome Limited	Sulfamides as zap-70 inhibitors
WO2009084693A1 (ja)	2007-12-28	2009-07-09	Mitsubishi Tanabe Pharma Corporation	抗癌剤
WO2009112490A1 (en)	2008-03-11	2009-09-17	Cellzome Limited	Sulfonamides as zap-70 inhibitors
WO2010015340A1 (en)	2008-08-06	2010-02-11	Bayer Schering Pharma Aktiengesellschaft	Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment
US8569288B2 (en)	2008-10-30	2013-10-29	Circomed Llc	Thienotriazolodiazepine derivatives active on apo A
EP2379559B1 (en)	2009-01-06	2017-10-25	Dana-Farber Cancer Institute, Inc.	Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
KR101779137B1 (ko)	2009-01-23	2017-09-18	다케다 야쿠힌 고교 가부시키가이샤	폴리(ａｄｐ-리보스)폴리머라제(ｐａｒｐ) 억제제
KR101553843B1 (ko) *	2009-07-31	2015-09-30	엘지전자 주식회사	가전기기 진단시스템 및 그 진단방법
GB0919431D0 (en)	2009-11-05	2009-12-23	Glaxosmithkline Llc	Novel compounds
GB0919423D0 (en)	2009-11-05	2009-12-23	Glaxosmithkline Llc	Novel compounds
GB0919426D0 (en) *	2009-11-05	2009-12-23	Glaxosmithkline Llc	Novel compounds
GB0919434D0 (en)	2009-11-05	2009-12-23	Glaxosmithkline Llc	Novel compounds
GB0919432D0 (en)	2009-11-05	2009-12-23	Glaxosmithkline Llc	Use
ES2563057T3 (es)	2009-11-05	2016-03-10	Glaxosmithkline Llc	Inhibidor de bromodominio de benzodiazepina
RS54645B1 (sr)	2009-11-05	2016-08-31	Glaxosmithkline Llc	Benzodiazepin kao inhibitor bromodomena
US8862173B2 (en)	2009-12-10	2014-10-14	Motorola Solutions, Inc.	Method for selecting media for delivery to users at an incident
EP2536725B1 (en)	2010-02-17	2015-10-28	Boehringer Ingelheim International GmbH	Dihydropteridinones, method for production and use thereof
WO2011162845A1 (en)	2010-03-26	2011-12-29	Rolls-Royce North American Technologies, Inc.	Adaptive fan system for a variable cycle turbofan engine
MX354217B (es)	2010-05-14	2018-02-19	Dana Farber Cancer Inst Inc	Composiciones y metodos para el tratamiento de leucemia.
JP5715241B2 (ja)	2010-05-14	2015-05-07	ダナ−ファーバーキャンサーインスティテュート，インコーポレイテッド	新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法
CN103180318B (zh)	2010-05-14	2017-05-10	达那-法伯癌症研究所	雄性避孕组合物以及使用方法
PL2902030T3 (pl)	2010-05-14	2017-07-31	Dana-Farber Cancer Institute, Inc.	Związki tienotriazolodiazepinowe do leczenia nowotworu
US9085582B2 (en)	2010-06-22	2015-07-21	Glaxosmithkline Llc	Benzotriazolodiazepine compounds inhibitors of bromodomains
NZ605874A (en)	2010-06-25	2015-02-27	Shire Human Genetic Therapies	Methods and compositions for cns delivery of heparan n-sulfatase
US20120014979A1 (en)	2010-07-16	2012-01-19	Alexander Dent	Use of bcl6 inhibitors for treating autoimmune diseases
TWI583689B (zh)	2010-08-04	2017-05-21	達納法柏癌症學院有限公司	治療腫瘤形成、發炎疾病及其他病症之組成物及方法
AR084070A1 (es)	2010-12-02	2013-04-17	Constellation Pharmaceuticals Inc	Inhibidores del bromodominio y usos de los mismos
US9249161B2 (en)	2010-12-02	2016-02-02	Constellation Pharmaceuticals, Inc.	Bromodomain inhibitors and uses thereof
US20130004481A1 (en)	2011-01-12	2013-01-03	Boehringer Ingelheim International Gmbh	Anticancer therapy
EP2677865A4 (en)	2011-02-23	2015-04-22	Icahn School Med Mount Sinai	BROMODOMAIN INHIBITORS AS MODULATORS OF GENE EXPRESSION
ES2951688T3 (es)	2011-02-28	2023-10-24	Epizyme Inc	Compuestos de heteroarilo biciclico fusionados en 6,5 sustituidos
US20120244209A1 (en)	2011-03-02	2012-09-27	Roth Jack A	Tusc2 therapies
JP2014524409A (ja)	2011-07-29	2014-09-22	ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア	Ｈｉｖの治療のための組成物および方法
WO2013033269A1 (en)	2011-08-29	2013-03-07	Coferon, Inc.	Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same
WO2013033270A2 (en)	2011-08-29	2013-03-07	Coferon, Inc.	Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same
FI20110279A7 (fi)	2011-08-29	2013-03-01	Outotec Oyj	Menetelmä metallien talteenottamiseksi niitä sisältävästä materiaalista
WO2013033420A1 (en)	2011-08-30	2013-03-07	Whitehead Institute For Biomedical Research	Methods of downregulating translocated oncogene expression using bromodomain inhibitors
DE102011082013A1 (de)	2011-09-01	2013-03-07	Bayer Pharma AG	6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
WO2013097052A1 (en)	2011-12-30	2013-07-04	Abbott Laboratories	Bromodomain inhibitors
US20130280332A1 (en)	2012-02-17	2013-10-24	Nexbio, Inc.	Methods, Compounds and Compositions for Treatment of Influenza and Parainfluenza Patients
WO2013148197A1 (en)	2012-03-28	2013-10-03	The J. David Gladstone Institutes	Compositions and methods for reactivating latent immunodeficiency virus
US9763956B2 (en)	2012-06-19	2017-09-19	The Broad Institute, Inc.	Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
CN104968334B (zh)	2012-09-28	2018-09-14	翁科埃斯克斯有限公司	包含噻吩并三唑并二氮杂卓化合物的药物制剂
US9567301B2 (en)	2012-11-02	2017-02-14	Dana-Farber Cancer Institute, Inc.	Pyrrol-1-yl benzoic acid derivatives useful as myc inhibitors
US20160009725A1 (en)	2013-02-22	2016-01-14	Bayer Pharma Aktiengesellschaft	Pyrrolo- and pyrazolo-triazolodiazepines as bet-protein inhibitors for treating hyperproliferative diseases
EP2958923A1 (de)	2013-02-22	2015-12-30	Bayer Pharma Aktiengesellschaft	4-substituierte pyrrolo- und pyrazolo-diazepine
AU2014223990A1 (en)	2013-02-28	2015-09-10	Washington University	Methods of treatment of human cytomegalovirus infection and diseases with bromodomain inhibitors
US9714946B2 (en)	2013-03-14	2017-07-25	Dana-Farber Cancer Institute, Inc.	Bromodomain binding reagents and uses thereof
JP2016519672A (ja)	2013-03-15	2016-07-07	ジェネンテック，インコーポレイテッド	ブロモドメイン含有タンパク質ｂｒｄ７およびｂｒｄ９の阻害によるｔｈ２媒介性疾患の治療
JP2016520130A (ja)	2013-05-28	2016-07-11	ダナ−ファーバーキャンサーインスティテュート，インコーポレイテッド	心臓疾患における新規治療戦略としてのｂｅｔ阻害
DE102013106353B4 (de)	2013-06-18	2018-06-28	Tdk Corporation	Verfahren zum Aufbringen einer strukturierten Beschichtung auf ein Bauelement
AU2014292888B2 (en)	2013-07-25	2018-03-22	Dana-Farber Cancer Institute, Inc.	Inhibitors of transcription factors and uses thereof
KR20160037201A (ko)	2013-08-06	2016-04-05	온코에틱스 게엠베하	Bet-브로모도메인 억제제를 사용한 미만성 거대 b-세포 림프종 (dlbcl)의 치료 방법
WO2015018522A1 (en)	2013-08-06	2015-02-12	Oncoethix Sa	Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
EP3033423A4 (en)	2013-08-16	2017-04-26	Rana Therapeutics Inc.	Epigenetic regulators of frataxin
US8988212B2 (en)	2013-08-22	2015-03-24	GM Global Technology Operations LLC	Electric vehicle pedestrian warning system
CA2922503C (en)	2013-09-19	2021-10-26	Dana-Farber Cancer Institute, Inc.	Methods of bh3 profiling
MX2016004570A (es)	2013-10-11	2016-09-08	Genentech Inc	Uso de inhibidores del bromodominio de cbp/ep300 para la inmunoterapia del cáncer.
CA2929652A1 (en)	2013-11-08	2015-05-14	Dana-Farber Cancer Institute, Inc.	Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
WO2015081284A1 (en)	2013-11-26	2015-06-04	Coferon, Inc.	Bivalent bromodomain ligands, and methods of using same
WO2015117087A1 (en)	2014-01-31	2015-08-06	Dana-Farber Cancer Institute, Inc.	Uses of diazepane derivatives
CA2936865A1 (en)	2014-01-31	2015-08-06	Dana-Farber Cancer Institute, Inc.	Diaminopyrimidine benzenesulfone derivatives and uses thereof
BR112016017045A2 (pt)	2014-01-31	2017-08-08	Dana Farber Cancer Inst Inc	Derivados de diazepano e usos dos mesmos
SG11201607108XA (en)	2014-02-28	2016-09-29	Tensha Therapeutics Inc	Treatment of conditions associated with hyperinsulinaemia
BR112017008714A2 (pt)	2014-10-27	2017-12-19	Tensha Therapeutics Inc	inibidores de bromodomínio
CA2969417A1 (en)	2014-12-05	2016-06-09	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Bromodomain inhibitor as adjuvant in cancer immunotherapy
CA2989313A1 (en)	2015-06-26	2016-12-29	Tensha Therapeutics, Inc.	Treatment of nut midline carcinoma
BR112018006689A2 (pt)	2015-10-02	2018-10-09	Dana Farber Cancer Inst Inc	terapia de combinação de inibidores de bromodomínio e bloqueio de ponto de controle

2015
- 2015-02-27 SG SG11201607108XA patent/SG11201607108XA/en unknown
- 2015-02-27 WO PCT/US2015/018118 patent/WO2015131113A1/en not_active Ceased
- 2015-02-27 AU AU2015222805A patent/AU2015222805B2/en not_active Ceased
- 2015-02-27 CA CA2940472A patent/CA2940472A1/en not_active Abandoned
- 2015-02-27 JP JP2016554661A patent/JP2017506666A/ja not_active Withdrawn
- 2015-02-27 US US15/121,964 patent/US10925881B2/en not_active Expired - Fee Related
- 2015-02-27 KR KR1020167026021A patent/KR20160130778A/ko not_active Ceased
- 2015-02-27 RU RU2016138027A patent/RU2722179C2/ru active
- 2015-02-27 MX MX2016011160A patent/MX377534B/es active IP Right Grant
- 2015-02-27 CN CN201580010875.2A patent/CN106456653A/zh active Pending
- 2015-02-27 EP EP15710997.6A patent/EP3110424A1/en not_active Withdrawn
2016
- 2016-08-18 IL IL247354A patent/IL247354B/en active IP Right Grant
2018
- 2018-11-28 JP JP2018222642A patent/JP6629947B2/ja not_active Expired - Fee Related

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006129623A1 (ja) *	2005-05-30	2006-12-07	Mitsubishi Tanabe Pharma Corporation	チエノトリアゾロジアゼピン化合物及びその医薬としての用途
WO2009084692A1 (ja) *	2007-12-28	2009-07-09	Nippon Telegraph And Telephone Corporation	可変焦点レンズ
JP2013527177A (ja) *	2010-05-14	2013-06-27	ダナ−ファーバーキャンサーインスティテュート，インコーポレイテッド	代謝を調節する組成物および方法
WO2012050907A2 (en) *	2010-09-28	2012-04-19	The Regents Of The University Of California	Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BIOCHEM. J., vol. 425(1), JPN6018038783, 2011, pages 71 - 83, ISSN: 0003892207 *
EUROPEAN JOURNAL OF ENDOCRINOLOGY, vol. 138, JPN6018038790, 1998, pages 269 - 274, ISSN: 0003892211 *
FEBS LETT., vol. 584(15), JPN6018038782, 2010, pages 3260 - 3268, ISSN: 0003892206 *
HEDRINGTON M S; FARMERIE S; ERTL A C; WANG Z; TATE D B; DAVIS S N: "EFFECTS OF ANTECEDENT GABAA ACTIVATION WITH ALPRAZOLAM ON COUNTERREGULATORY 以下備考", DIABETES, vol. VOL:59, NR:4, JPN5017001336, April 2010 (2010-04-01), pages 1074 - 1081, ISSN: 0003892208 *
NATURE, vol. 7327, JPN6018038787, 2010, pages 1067 - 1073, ISSN: 0003892210 *
PLOS ONE, vol. 3(12), JPN6018038785, 2008, pages 3850, ISSN: 0003892209 *

Also Published As

Publication number	Publication date
JP6629947B2 (ja)	2020-01-15
IL247354A0 (en)	2016-11-30
EP3110424A1 (en)	2017-01-04
RU2016138027A3 (2)	2018-10-29
MX377534B (es)	2025-03-10
KR20160130778A (ko)	2016-11-14
JP2019059751A (ja)	2019-04-18
RU2016138027A (ru)	2018-04-03
IL247354B (en)	2020-06-30
US10925881B2 (en)	2021-02-23
RU2722179C2 (ru)	2020-05-28
CA2940472A1 (en)	2015-09-03
WO2015131113A1 (en)	2015-09-03
CN106456653A (zh)	2017-02-22
MX2016011160A (es)	2017-04-27
AU2015222805A1 (en)	2016-09-15
AU2015222805B2 (en)	2020-05-21
SG11201607108XA (en)	2016-09-29
US20170209461A1 (en)	2017-07-27

Legal Events

Date	Code	Title	Description
2018-01-11	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180111
2018-01-11	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180111
2018-09-28	A977	Report on retrieval	Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180926
2018-10-03	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181003
2018-10-22	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181022
2018-11-30	A761	Written withdrawal of application	Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20181130
2018-12-28	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181210

Publication	Publication Date	Title
JP6629947B2 (ja)	2020-01-15	高インスリン血症に関連した症状の処置
JP7838004B2 (ja)	2026-03-31	Ｐｏｌｙｂｒｏｍｏ－１（ｐｂｒｍ１）の小分子分解剤
JP2021193128A (ja)	2021-12-23	補体媒介障害の治療のためのアリール化合物、ヘテロアリール化合物及び複素環式化合物
AU2021200164B2 (en)	2022-09-08	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
AU2017393082B2 (en)	2022-04-21	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN112672997A (zh)	2021-04-16	哒嗪酮衍生物
KR20170068597A (ko)	2017-06-19	브로모도메인 저해제
TW201506018A (zh)	2015-02-16	二雜芳基化合物及其用途
KR20220130697A (ko)	2022-09-27	새로운 화합물 및 그 용도
CA3012882A1 (en)	2017-08-03	Fused pyrazole derivatives, preparation method thereof, and use thereof in treatment of cancers, inflammation and immune diseases
JP2024160326A (ja)	2024-11-13	Ｅａａｔ２活性化因子およびその使用方法
CN108463222B (zh)	2021-10-22	用于治疗疾病的杂环化合物
CA2916419A1 (en)	2015-03-19	Substituted 2, 3-dihydro-1h-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis
JP6542236B2 (ja)	2019-07-10	有機化合物
JP2015523352A (ja)	2015-08-13	Ｋａｔｉｉ阻害剤としての三環式化合物
KR19990067528A (ko)	1999-08-25	카인산 신경 세포 독성 억제제 및 피리도티아진 유도체
JP2025003966A (ja)	2025-01-14	キノンレダクターゼ２阻害剤化合物およびその使用
US5580877A (en)	1996-12-03	Pyrazolo-quinoline derivatives for treating cerebral ischemia
CN118480047A (zh)	2024-08-13	加兰他敏衍生物及其用途
US20200392126A1 (en)	2020-12-17	Isoxazolyl compounds as receptor modulating compounds and methods and uses thereof
HK40070316A (en)	2022-10-28	Heterocyclic compounds for the treatment of disease
KR20260001534A (ko)	2026-01-05	신규한 이종이작용기 단백질 분해제 및 이의 용도
WO2020059841A1 (ja)	2020-03-26	プリオン病治療薬
EA046894B1 (ru)	2024-05-07	Ингибиторы rho-ассоциированной, содержащей суперспираль протеинкиназы
US20200181128A1 (en)	2020-06-11	3-hydroxy-imidazolidin-4-one compounds as inhibitors of indoleamine 2,3-dioxygenase